Helicobacter pylori Infection - Biotech, Pharma and Life Science Channel

14:17 EDT 22nd September 2014 | BioPortfolio

PubMed Articles [6788 Associated PubMed Articles listed on BioPortfolio]

Intermittent or sustained systemic inflammation and the preterm brain.

Exposure to perinatal infection and inflammation is associated with an increased risk for neonatal brain damage and developmental disabilities. In this integrated mechanism review, we discuss evidence...

Rapid detection and differentiation of important Campylobacter spp. in poultry samples by dot blot and PCR.

The detection of Campylobacter, the most commonly reported cause of foodborne gastroenteritis in the European Union, is very important for human health. The most commonly recognised risk factor for in...

Renal Pathology: SY23-2 A CASE OF A NEW DISEASE ENTITY: PODOCYTIC INFOLDING GLOMERULOPATHY.

A 41-year-old woman was discovered to have enteric infection of Aeromonas caviae and was treated with antibiotics. Subsequently she developed nephrotic syndrome. Renal biopsy showed a non-argentaffine...

Pulmonary Pathology: LC22-1 PATHOLOGICAL DIVERSITY OF PULMONARY TUBERCULOSIS.

Tuberculosis (TB), a multi-systemic disease with myriad presentations and variable manifestations, is endemic in almost every part of the world and continues to remain the most common cause of infecti...

Pediatric and Perinatal Pathology: SY21-4 HTLV-1 INFECTION IN CHILDREN.

Human lymphotropic virus type I (HTLV-I) is endemic in Jamaica and is transmitted from mother to infant via breast milk. Thirty-two percent of those breastfed for ≥12 months show seroconversion but ...

Pediatric and Perinatal Pathology: SY21-2 INVASIVE PULMONARY ASPERGILLOSIS IN A PREMATURE NEONATE.

The incidence of opportunistic invasive infections has risen dramatically in the last years and morbidity and mortality remains high. Invasive aspergillosis has been described in immunocompromised pat...

Neuropathology: SY21-2 MUCOR FUNGAL ENCEPHALITIS: CASE PRESENTATION.

Mucormycosis is a rare and often fatal infection caused by fungi of the Mucorales order, commonly affecting immunocompromised patients and adults with diabetic ketoacidosis. Infants are infected throu...

Infectious Diseases and Tropical Disease Pathology: SY16-3 PYTHIOSIS: AN ENDEMIC FATAL INFECTIOUS DISEASE.

Pythiosis is a life threatening infectious disease of humans and animals living in tropical and subtropical areas of the world. The causative agent is the fungus-like microorganism Pythium insidiosum,...

Infectious Diseases and Tropical Disease Pathology: SY16-3 OPISTHORCHIASIS: FROM PATHOGENESIS TO CONTROL.

Opisthorchiasis caused by Opisthorchis viverrini infection is a major public health in Thailand and neighboring Mekong countries. The infection is associated with cholangitis, cholecystitis, gallstone...

Infectious Diseases and Tropical Disease Pathology: SY16-2B PEDIATRIC CEREBRAL MALARIA PATHOLOGY.

Malaria kills more than half a million children a year in sub-Saharan Africa despite the availability of effective combination drug therapy, efficacy of bed nets, and environmental control measures. C...

News Articles [2290 Associated News Articles listed on BioPortfolio]

Nitrogen metabolism in Mycobacterium tuberculosis physiology and virulence

The crosstalk between the metabolic pathways of intracellular pathogens and host cells can have important consequences for infection. In this Progress article, Neyrolles and colleagues describe recent...

Medtronic Announces CE Mark and European Launch of TYRX(TM) Absorbable Antibacterial Envelope

MINNEAPOLIS - Sept. 22, 2014 - Medtronic, Inc. (NYSE: MDT) has received CE (Conformité Européenne) Mark for the TYRX(TM) Absorbable Antibacterial Envelope. This innovative mesh envelope cover...

Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants

Gibbons et al. show that T cells in newborns, previously thought to have a limited ability to fight infection, can produce interleukin-8, an effector of innate immunity.

Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions

PHOENIX, Sept. 22, 2014 /PRNewswire/ -- For many people experiencing issues with their hands or wrists, surgery often means facing the prospect of large, painful incisions and long recovery time....

Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014

LITTLE FALLS, N.J., Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN) will release  the results for its fourth quarter and fiscal 2014 ended July 31, 2014 on Monday, September 2...

SLU researcher to study new hepatitis C medication in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

New research identifies novel cellular factors vital for CCHFV infection

New research into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne virus which causes a severe hemorrhagic disease in humans similar to that caused by Ebolavirus, has identified new cel...

Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from Pulmo...

Influenza A potentiates pneumococcal co-infection: New details emerge

(American Society for Microbiology) Influenza infection can enhance the ability of the bacterium Streptococcus pneumoniae to cause ear and throat infections, according to research published ahead of p...

Sanofi's New Drug Is Potentially A Game Changer

By Apex Financial Consultants:Sanofi SA (NYSE:SNY) is all set to make dengue a vaccine-preventable disease after 20 years of research and industrial commitment. In clinical trials the company's experi...

Events [0 Results]

None

Companies [52 Associated Companies listed on BioPortfolio]

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Forest Laboratories, Inc. and Furiex Pharmaceuticals, Inc.

Forest Laboratories (NYSE: FRX) is a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market. Forest markets a portfolio of branded...

Ichor Medical Systems, Inc.

Ichor Medical Systems’ TriGrid™ Delivery System (TriGrid) is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. I...

Adenovir Pharma AB

Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes. Adenovir Pharma was founded by researchers at the department of Virolo...

TICK TOCK Naturals LLC

TICK TOCK Naturals™ Organic Insect Repellent is a concentrated 100% organic, chemical-free insect repellent that is also cruelty-free and made in the U.S. It was formulated a...

Special Phage Services

Few inventions in science and medicine have had such a profound effect on human health as the discovery and subsequent development of antibiotics. Following their introduction during World War II ma...

Fidelis Diagnostics, Inc.

Headquartered in Los Angeles, Fidelis Diagnostics is a rapidly growing healthcare company providing a portfolio of innovative diagnostic services to physicians nationwide. Since i...

TYRX®, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISRx® Antibacterial Envelope, designed to redu...

Progenra, Inc.

Founded in 2002, Progenra is committed to discovering and developing high value medicines based on ubiquitin and ubiquitin-like protein pathways. Its early stage product portfolio...

CytoDyn Inc.

CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and pr...

Clinical Trials [1412 Associated Clinical Trials listed on BioPortfolio]

MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

The study will evaluate the efficacy and safety of MK-8228 for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem...

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical be...

University of Wisconsin Meditation & Exercise Cold Study

The primary goal of this project is to determine whether behavioral training in mindfulness meditation or moderate intensity sustained exercise will lead to reductions in acute respiratory...

Impact of Rapid Detection of MRSA

The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized...

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HI...

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Participants With Hepatitis C Infection (MK-8408-003)

This is a 3-part study of MK-8408 for participants with hepatitis C infection. Successive participants will be enrolled as dose levels are evaluated to find the maximum safe and well tole...

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

This study will determine the HCV antiviral efficacy, safety, and tolerability of treatment with Ledipasvir/Sofosbuvir (LDV/SOF) fixed-dose combination (FDC) for participants with genotype...

A Multiple Dose Study of MK-5172 in Hepatitis C-Infected Participants (MK-5172-010)

This study will compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of MK-5172 to participants with chronic hepatitis C virus (HCV) infection....

CPP Bone Infection Registry

Establish an international registry of over 400 patients with deep infections involving the bone and/or joint from≥20 centers representing all regions of the world with varied hospital a...

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection

Aim of the study is to assess the efficacy and safety of 24 weeks of oral Sofosbuvir/Ledipasvir fixed-dose combination (FDC) in subjects with HCV genotype 1 infection and HIV co-infection,...

Medical and Biotech [MESH] Definitions

Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.

A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).

A species of gram-negative, spiral-shaped bacteria found in the gastric mucosa that is associated with chronic antral gastritis. This bacterium was first discovered in samples removed at endoscopy from patients investigated for HELICOBACTER PYLORI colonization.

Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).

Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Helicobacter pylori Infection market research data and corporate reports here

Channels Quicklinks